Alector Inc - ESG Rating & Company Profile powered by AI
Complete ESG analysis of Alector Inc can be accessed by logging in. The webpage displays a zero-cost Environmental, Social and Governance report covering Alector Inc. The assessment of Alector Inc uses data points from across the web as well as from available disclosures by Alector Inc.
Alector Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.9; made up of an environmental score of 1.3, social score of 3.4 and governance score of 4.0.
2.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1336 | SyneuRx International (Taiwan) Corp | 3.0 | Medium |
| 1336 | Sensorion SA | 3.0 | Medium |
| 1353 | Alector Inc | 2.9 | Medium |
| 1353 | Caribou Biosciences Inc | 2.9 | Medium |
| 1353 | Checkmate Pharmaceuticals Inc | 2.9 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Alector Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Alector Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Alector Inc report the average age of the workforce?
Sign up for free to unlockDoes Alector Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Alector Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Alector Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Alector Inc offer flexible work?
Sign up for free to unlockDoes Alector Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Alector Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Alector Inc conduct supply chain audits?
Sign up for free to unlockDoes Alector Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Alector Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Alector Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Alector Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Alector Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Alector Inc disclose water use targets?
Sign up for free to unlockDoes Alector Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Alector Inc have a product recall in the last two years?
Sign up for free to unlockDoes Alector Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Alector Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Alector Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Alector Inc disclose parental leave metrics?
Sign up for free to unlockDoes Alector Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Alector Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Alector Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Alector Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Alector Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Alector Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Alector Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Alector Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Alector Inc disclose its waste policy?
Sign up for free to unlockDoes Alector Inc report according to TCFD requirements?
Sign up for free to unlockDoes Alector Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Alector Inc disclose energy use targets?
Sign up for free to unlockDoes Alector Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Alector Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Alector Inc
These potential risks are based on the size, segment and geographies of the company.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.